Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 117, Issue 12, Pages 3633-3641Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI34129
Keywords
-
Categories
Funding
- NIAID NIH HHS [R01 AI071068, AI071068] Funding Source: Medline
- NIDDK NIH HHS [DK078424, R01 DK078424] Funding Source: Medline
Ask authors/readers for more resources
With unprecedented speed, RNA interference (RNAi) has advanced from its basic discovery in lower organisms to becoming a powerful genetic tool and perhaps our single most promising biotherapeutic for a wide array of diseases. Numerous studies document RNAi efficacy in laboratory animals, and the first clinical trials are underway and thus far suggest that RNAi is safe to use in humans. Yet substantial hurdles have also surfaced and must be surmounted before therapeutic RNAi applications can become a standard therapy. Here we review the most critical roadblocks and concerns for clinical RNAi transition, delivery, and safety. We highlight emerging solutions and concurrently discuss novel therapeutic RNAi-based concepts. The current rapid advances create realistic optimism that the establishment of RNAi as a new and potent clinical modality in humans is near.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available